Humacyte Inc (HUMA) - Total Assets
Based on the latest financial reports, Humacyte Inc (HUMA) holds total assets worth $116.37 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore HUMA operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Humacyte Inc - Total Assets Trend (2019–2025)
This chart illustrates how Humacyte Inc's total assets have evolved over time, based on quarterly financial data. See shareholders equity of Humacyte Inc for net asset value and shareholders' equity analysis.
Humacyte Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Humacyte Inc's total assets of $116.37 Million consist of 58.3% current assets and 41.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 43.4% |
| Accounts Receivable | $441.00K | 0.4% |
| Inventory | $13.59 Million | 11.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Humacyte Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Humacyte Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Humacyte Inc's current assets represent 58.3% of total assets in 2025, an increase from 56.3% in 2019.
- Cash Position: Cash and equivalents constituted 43.4% of total assets in 2025, down from 55.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is inventory at 11.7% of total assets.
Humacyte Inc Competitors by Total Assets
Key competitors of Humacyte Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND
|
USA | $2.01 Billion |
|
ALTEOGEN Inc
KQ:196170
|
Korea | ₩729.47 Billion |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE
|
USA | $1.29 Billion |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX
|
USA | $440.10 Million |
|
Neuren Pharmaceuticals Ltd
AU:NEU
|
Australia | AU$331.25 Million |
|
Galapagos N.V.
AS:GLPG
|
Netherlands | €3.37 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
Humacyte Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.69 | 2.40 | 3.03 |
| Quick Ratio | 2.95 | 2.40 | 3.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $49.42 Million | $27.91 Million | $30.93 Million |
Humacyte Inc - Advanced Valuation Insights
This section examines the relationship between Humacyte Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 76.41 |
| Latest Market Cap to Assets Ratio | 1.25 |
| Asset Growth Rate (YoY) | -15.6% |
| Total Assets | $116.37 Million |
| Market Capitalization | $144.98 Million USD |
Valuation Analysis
Above Book Valuation: The market values Humacyte Inc's assets above their book value (1.25x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Humacyte Inc's assets decreased by 15.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Humacyte Inc (2019–2025)
The table below shows the annual total assets of Humacyte Inc from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $116.37 Million | -15.60% |
| 2024-12-31 | $137.87 Million | +7.53% |
| 2023-12-31 | $128.22 Million | -37.24% |
| 2022-12-31 | $204.30 Million | -28.70% |
| 2021-12-31 | $286.53 Million | +168.57% |
| 2020-12-31 | $106.69 Million | -36.76% |
| 2019-12-31 | $168.69 Million | -- |
About Humacyte Inc
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to b… Read more